Based on the key indicators related to Edgewise Therapeutics' liquidity, profitability, solvency, and operating efficiency, Edgewise Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, Edgewise Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Property Plant And Equipment Net is likely to rise to about 13.3 M in 2024, whereas Total Assets are likely to drop slightly above 252.6 M in 2024. Key indicators impacting Edgewise Therapeutics' financial strength include:
Investors should never underestimate Edgewise Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Edgewise Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in Edgewise Therapeutics.
Net Income
(95.15 Million)
Edgewise
Select Account or Indicator
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Cash Per Share
Pocfratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Capex Per Share
Graham Net Net
Enterprise Value Over E B I T D A
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Return On Capital Employed
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Free Cash Flow Operating Cash Flow Ratio
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Return On Assets
Price Fair Value
Return On Equity
Investments
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Operating Activities
Issuance Of Capital Stock
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Netincome
Change To Liabilities
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Tangible Assets
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Cash And Short Term Investments
Common Stock Shares Outstanding
Short Term Investments
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Net Invested Capital
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Capital Stock
Net Working Capital
Property Plant Equipment
Non Currrent Assets Other
Other Assets
Net Interest Income
Interest Income
Depreciation And Amortization
Interest Expense
Selling General Administrative
Gross Profit
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Reconciled Depreciation
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Probability Of Bankruptcy
Understanding current and past Edgewise Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Edgewise Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Edgewise Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Edgewise Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Edgewise Therapeutics. Check Edgewise Therapeutics' Beneish M Score to see the likelihood of Edgewise Therapeutics' management manipulating its earnings.
Edgewise Therapeutics Stock Summary
Edgewise Therapeutics competes with Lyra Therapeutics, Hookipa Pharma, SAB Biotherapeutics, Cadrenal Therapeutics,, and Monopar Therapeutics. Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado. Edgewise Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 42 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Edgewise Therapeutics's current stock value. Our valuation model uses many indicators to compare Edgewise Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Edgewise Therapeutics competition to find correlations between indicators driving Edgewise Therapeutics's intrinsic value. More Info.
Edgewise Therapeutics is rated # 2 in return on equity category among its peers. It is rated # 5 in return on asset category among its peers . At this time, Edgewise Therapeutics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Edgewise Therapeutics' earnings, one of the primary drivers of an investment's value.
Edgewise Therapeutics Systematic Risk
Edgewise Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Edgewise Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on Edgewise Therapeutics correlated with the market. If Beta is less than 0 Edgewise Therapeutics generally moves in the opposite direction as compared to the market. If Edgewise Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Edgewise Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Edgewise Therapeutics is generally in the same direction as the market. If Beta > 1 Edgewise Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Edgewise Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Edgewise Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Edgewise Therapeutics growth as a starting point in their analysis.
Edgewise Therapeutics November 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Edgewise Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Edgewise Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Edgewise Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Edgewise Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Edgewise Therapeutics's daily price indicators and compare them against related drivers.
When running Edgewise Therapeutics' price analysis, check to measure Edgewise Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edgewise Therapeutics is operating at the current time. Most of Edgewise Therapeutics' value examination focuses on studying past and present price action to predict the probability of Edgewise Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edgewise Therapeutics' price. Additionally, you may evaluate how the addition of Edgewise Therapeutics to your portfolios can decrease your overall portfolio volatility.